Home > PF-06843195

molecules of the month

<< Back to December

Structure of oral PI3K_-selective kinase inhibitor prodrug PF-06843195

PF-06843195

Recent Publication

oral PI3K_-selective kinase inhibitor prodrug

preclinical candidate for breast cancer

from mining of prior PI3K inh., SBDD, and opt.

J. Med. Chem., Dec. 24, 2020

Pfizer, San Diego, CA

Pfizer oral PI3ka-selective kinase inhibitor prodrug

this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.